Clinical Application of Chinese Herbal Injection for Cancer Care: Evidence-Mapping of the Systematic Reviews, Meta-analyses, and Randomized Controlled Trials

Yang, Ming; Zhu, Sijia; Shen, Chen; Zhai, Rui; Li, Duoduo; Fang, Min; Xu, Jingnan; Gan, Yena; Yang, Lu; Ren, Zhiying; Zheng, Ruo-xiang; Robinson, Nicola; Liu, Jianping

doi:10.3389/fphar.2021.666368

Cited by 30 publications

(30 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serving as anticancer CHIs, they are generally accepted in TCM hospitals. Multiple studies in China concluded that different CHIs have similar but uneven positive impacts on cancer patients [ 8 ]. However, the usage of anticancer CHIs has not been unified, which limits the development of these TCM injections.…”

Section: Discussionmentioning

confidence: 99%

“…The Chinese herbal injection (CHI) is based on the theories of traditional Chinese medicine (TCM), and the application of which is a symbol of the modernization of TCM. Currently, over a dozen CHIs are frequently used in treating human cancer: Aidi, Astragalus polysaccharides, Brucea javanica oil emulsion, Cinobufacini, compound matrine, Delisheng, ginseng polysugar, Kangai, Kanglaite, and Shenqifuzheng [ 7 ] The majority studies of these anticancer CHIs are related to lung cancer, and it is concluded that CHIs can reduce ADRs during chemotherapy and promote patients' QOL, which has been demonstrated by evidence-based medicine [ 8 ]. Most of the reports published in English were reviews or meta-analyses, which were based on similar studies previously published in Chinese.…”

Section: Introductionmentioning

confidence: 99%

“…Aidi injection (ADI) and Brucea javanica oil emulsion injection (BJOEI; Yadanziyouru injection) are both common CHIs for many malignant tumors. It is generally accepted in TCM that CRC, a disease with deficiency of both spleen and kidney, can result better in survival outcome by regulating the immune microenvironment from these TCM drugs [ 8 ]. For advanced CRC patients, the two CHIs also show survival benefits as the palliative treatments.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

[Retracted] Efficacy of Aidi Injection and Brucea javanica Oil Emulsion Injection in Rectal Cancer during CapeOX Adjuvant Chemotherapy

Meng

Zeng

Gao

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Background. Adjuvant chemotherapy with CapeOX regimen is widely used in resected rectal cancer, which brings benefits to patients. But drug-related toxicities are severe during this process; thus, survival outcomes may potentially be affected. This study explored the efficacy of two Chinese herbal injections, Aidi injection (ADI) and Brucea javanica oil emulsion injection (BJOEI), as adjuvant drugs in CapeOX adjuvant chemotherapy on rectal cancer patients. Methods. A total of 240 cases were enrolled in this retrospective study. 80 cases received CapeOX with ADI (the ADI group), 80 cases received CapeOX with BJOEI (the BJOEI group), and the rest 80 cases received CapeOX alone (the control group). After four cycles’ chemotherapy, adverse reactions (ADRs) and quality of life (QOL) were analyzed. Then, patients received follow-up for at least one year, and the endpoint was disease-free survival (DFS). Results. All patients completed at least four cycles’ adjuvant chemotherapy. The incidence of leukopenia and thrombocytopenia was significantly lower in the ADI group; the incidence of nausea was significantly lower in the BJOEI group; the incidence of hand-foot syndrome was significantly lower in both the ADI group and BJOEI group. Significant difference was found in the control group regarding the Karnofsky Performance Status (KPS) scores prior and posttreatment. No difference was found among three groups regarding one-year DFS. Conclusion. As adjuvant drugs for rectal cancer during CapeOX chemotherapy, ADI shows advantages in decreasing leukopenia and thrombocytopenia, while BJOEI results better in remitting nausea. Both two CHIs had positive impacts on decreasing hand-foot syndrome and the maintenance of patients’ QOL. It is worthy of further study and promotion for CHIs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

[Retracted] Efficacy of Aidi Injection and Brucea javanica Oil Emulsion Injection in Rectal Cancer during CapeOX Adjuvant Chemotherapy

Meng

Zeng

Gao

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Traditional Chinese medicine (TCM) has been widely used as an adjuvant therapeutic option for cancer treatment (Xiang et al, 2019;Liu S.-H. et al, 2021). High-level clinical studies of TCM injection in cancer care has gradually increased (Yang et al, 2021). Kanglaite injection had been approved by the Chinese State Food and Drug Administration (SFDA) for the treatment of various malignant tumors.…”

Section: Introductionmentioning

confidence: 99%

Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis

Kong

Wang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Kanglaite(KLT), a type of Chinese medicine preparation, is considered as an adjuvant therapeutic option for malignant cancer treatment. This study aimed to systematically investigate the efficacy and safety of the combination of KLT and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for the treatment of stage III/IV non-small cell lung cancer.Methods: Randomized controlled trials (RCTs) that compared KLT plus EGFR-TKI with EGFR-TKI alone for the treatment of stage III/IV non-small cell lung cancer were reviewed. Literature searches (up to July 10, 2021) were performed on PubMed, Web of Science, Cochrane Library, Embase, ClinicalTrials.gov, China National Knowledge Infrastructure (CNKI), Wanfang Database, and the Chinese Scientific Journal Database. Two researchers independently assessed the risk of bias with the tool of Cochrane Collaboration. RevMan 5.3.0 was used in the analysis of the included trial data.Results: 12 RCTs recruiting 1,046 patients with stage III/IV NSCLC were included. Results showed that compared with EGFR-TKI alone, KLT plus EGFR-TKI significantly increased the disease control rate (DCR) (odds ratio [OR]=3.26; 95% confidence interval [CI]:2.22–4.77; p < 0.00001), the objective response rate (ORR) (OR=2.59; 95% CI:1.87–3.58; p < 0.00001) and Karnofsky performance status (KPS) (OR = 2.76; 95% CI:1.73–4.39; p < 0.00001). Furthermore, patient immunity was enhanced with KLT plus EGFR-TKI. The combined treatment increased the percentage of CD4 + T cells (weighted mean difference [WMD]=5.36; 95% CI:3.60–7.13; p < 0.00001),the CD4+/CD8 + ratio (WMD = 0.18; 95% CI: 0.08–0.27; p = 0.004), and percentage of NK cells (WMD=4.84; 95% CI: 3.66–6.02; p < 0.00001).With regard to drug toxicity, the occurrence rate of nausea and vomiting was significantly reduced by KLT plus EGFR-TKI (OR=0.37; 95% CI: 0.16–0.86; p = 0.02).Conclusion: KLT plus EGFR-TKI was effective in treating stage III/IV non-small cell lung cancer. Thus, its application in these patients is worth promoting. Additional double-blind, well-designed and multicenter RCTs are required to confirm the efficacy and safety of this treatment.

show abstract

“…Traditional Chinese herbal medicine has received increasing attention. The reason is that Chinese herbs are derived from plants with evidences of high safety and less adverse effects [25,26]. Danshen has been used as a healthy food and as medicine for approximately 1000 years.…”

Section: Discussionmentioning

confidence: 99%

Dihydroisotanshinone I as a Treatment Option for Head and Neck Squamous Cell Carcinomas

Hsu

Yang

Tsai

et al. 2021

IJMS

View full text Add to dashboard Cite

Head and neck squamous cell carcinomas (HNSCCs) are the most common cancers of the head and neck, and their prevalence is rapidly increasing. HNSCCs present a clinical challenge because of their high recurrence rate, therapeutic resistance to radiation and chemotherapy drugs, and adverse effects. Hence, traditional Chinese herbal treatment may be advantageous to therapeutic strategies for HNSCCs. Danshen (Salvia miltiorrhiza), a well-known Chinese herb, has been extensively applied in treatments for various diseases, including cancer, because of its high degree of safety and low rate of adverse effects despite its unclear mechanism. Thus, we aimed to explore the possible anticancer effects and mechanisms of dihydroisotanshinone I (DT), a compound in danshen (extract from danshen), on HNSCCs. Three HNSCCs cell lines were used for in vitro studies, and a Detroit 562 xenograft mouse model was chosen for in vivo studies. Our in vitro results showed that DT could initiate apoptosis, resulting in cell death, and the p38 signaling partially regulated DT-initiated cell apoptosis in the Detroit 562 model. In the xenograft mouse model, DT reduced tumor size with no obvious adverse effect of hepatotoxicity. The present study suggests that DT is a promising novel candidate for anti-HNSCCs therapy.

show abstract

Clinical Application of Chinese Herbal Injection for Cancer Care: Evidence-Mapping of the Systematic Reviews, Meta-analyses, and Randomized Controlled Trials

Cited by 30 publications

References 18 publications

[Retracted] Efficacy of Aidi Injection and Brucea javanica Oil Emulsion Injection in Rectal Cancer during CapeOX Adjuvant Chemotherapy

[Retracted] Efficacy of Aidi Injection and Brucea javanica Oil Emulsion Injection in Rectal Cancer during CapeOX Adjuvant Chemotherapy

Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis

Dihydroisotanshinone I as a Treatment Option for Head and Neck Squamous Cell Carcinomas

Contact Info

Product

Resources

About